Matinas BioPharma to Present Positive Preclinical Data of MAT2203 at the 28th European Congress of Clinical Microbiology and ...
April 19 2018 - 8:05AM
Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage
biopharmaceutical company focused on developing innovative
anti-infectives for orphan indications, today announced that it
will present a poster at the 28th European Congress of Clinical
Microbiology and Infectious Diseases (ECCMID), being held April
21-24, 2018, in Madrid, Spain. The Company’s lead product
candidate, MAT2203, is an orally-administered cochleate formulation
of a broad spectrum anti-fungal drug called amphotericin B. Matinas
is initially developing MAT2203 for the prevention of invasive
fungal infections due to immunosuppressive therapy, particularly in
patients with acute lymphoblastic leukemia.
Title: Efficacy of oral
amphotericin B-cochleates for the prevention of invasive
candidiasis caused by Candida albicans in micePresenting
Author: David S. Perlin, Ph.D., Member of Matinas’
Scientific Advisory Board, Executive Director of the Public Health
Research Institute (PHRI) and the Rutgers Regional Biocontainment
Laboratory (RBL) of New Jersey Medical School (NJMS), Rutgers
Biomedical and Health Sciences, and Professor of Microbiology,
Biochemistry and Molecular Genetics at NJMSDate and
Time: April 24, 2018 at 12:30 PM CETPoster
Presentation #: P2363Session: Recent
findings in invasive candidiasis
The ECCMID 2018 abstract is available online at
the conference website. Following the event, the poster will be
available on the Company's website in the Scientific Presentations
section. About MAT2203
MAT2203 is an orally-administered, encochleated
formulation of amphotericin B (a broad spectrum fungicidal agent).
Little to no clinical resistance has been reported to date with
amphotericin B as compared to the rapidly emerging drug resistance
seen in other antifungal therapies. Currently, IV-only administered
amphotericin B is the only broad spectrum fungicidal available but
its IV-delivery results in significant treatment-limiting side
effects, including nephrotoxicity. The ability to provide
amphotericin B orally using our proprietary and novel oral
formulation may offer a new and promising alternative for patients
and doctors. The FDA has designated MAT2203 as a Qualified
Infectious Disease Product (QIDP) for the treatment of invasive
candidiasis and the treatment of aspergillosis, as well as for the
prevention of invasive fungal infections due to immunosuppressive
therapy. MAT2203 is also being explored for treatment of additional
anti-fungal indications and may have the potential for Orphan Drug
Designation in certain of these indications.
About Matinas BioPharma Matinas
BioPharma is a clinical-stage biopharmaceutical company focused on
developing innovative anti-infectives for orphan indications. The
Company's proprietary, disruptive technology utilizes lipid-crystal
nano-particle cochleates to nano-encapsulate existing drugs, making
them safer, more tolerable, less toxic and orally bioavailable. The
Company's lead anti-infective product candidates, MAT2203 and
MAT2501, position Matinas BioPharma to become a leader in the safe
and effective delivery of anti-infective therapies utilizing its
proprietary lipid-crystal nano-particle cochleate formulation
technology.
For more information, please visit
www.matinasbiopharma.com and connect with the Company on Twitter,
LinkedIn, Facebook, and Google+.
Forward Looking Statements:
This release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995,
including those relating to the Company's anticipated capital and
liquidity needs, strategic focus and the future development of its
product candidates, including MAT2203, the anticipated timing of
regulatory submissions, the anticipated timing of clinical studies,
the anticipated timing of regulatory interactions, the Company’s
ability to identify and pursue development and partnership
opportunities for its products or platform delivery technology on
favorable terms, if at all, and the ability to obtain required
regulatory approval and other statements that are predictive in
nature, that depend upon or refer to future events or conditions.
All statements other than statements of historical fact are
statements that could be forward-looking statements.
Forward-looking statements include words such as "expects,"
"anticipates," "intends," "plans," "could," "believes," "estimates"
and similar expressions. These statements involve known and unknown
risks, uncertainties and other factors which may cause actual
results to be materially different from any future results
expressed or implied by the forward-looking statements.
Forward-looking statements are subject to a number of risks and
uncertainties, including, but not limited to, our ability to obtain
additional capital to meet our liquidity needs on acceptable terms,
or at all, including the additional capital which will be necessary
to complete the clinical trials of our product candidates; our
ability to successfully complete research and further development
and commercialization of our product candidates; the uncertainties
inherent in clinical testing; the timing, cost and uncertainty of
obtaining regulatory approvals; our ability to maintain and derive
benefit from the Qualified Infectious Disease Product (QIDP),
Orphan and/or Fast Track designations for MAT2203, which does not
change the standards for regulatory approval or guarantee
regulatory approval on an expedited basis, or at all; our ability
to protect the Company's intellectual property; the loss of any
executive officers or key personnel or consultants; competition;
changes in the regulatory landscape or the imposition of
regulations that affect the Company's products; and the other
factors listed under "Risk Factors" in our filings with the SEC,
including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to
place undue reliance on such forward-looking statements, which
speak only as of the date of this release. Except as may be
required by law, the Company does not undertake any obligation to
release publicly any revisions to such forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. Matinas BioPharma's
product candidates are all in a development stage and are not
available for sale or use.
Investor ContactJenene ThomasJenene Thomas
Communications, LLCPhone: +1 (833) 475-8247Email:
mtnb@jtcir.com |
Media
ContactEliza Schleifstein Scient Public RelationsPhone: +
1 (917) 763-8106 Email: eliza@scientpr.com |
Source: Matinas BioPharma Holdings, Inc.
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Sep 2023 to Sep 2024